CMS has released a clinical super intelligence roadmap outlining how the federal government plans to regulate and pay for AI in healthcare, including potential Medicare payment for AI-led care.
The Nov. 13 roadmap uses “super intelligence,” the Trump administration’s term for what it formerly called AI. It rests on four pillars: earning public trust, building the data foundation, establishing clear rules of the road and paying for what works.
Seven notes:
1. CMS will hold clinical AI to a “better than today” standard for safety, effectiveness, access and outcomes, not a standard of perfection. Greater autonomy must be earned through evidence, staged deployment and real-world monitoring.
2. CMS anticipates creating structures for AI-led solutions to participate in CMS Innovation Center primary care and total-cost-of-care models. Those solutions would need partnerships with clinicians and facilities to escalate patients to humans. CMS also aims to foster AI-led insurance options in Medicare Advantage and the ACA marketplaces.
3. CMS plans to extend its Advancing Chronic Care with Effective, Scalable Solutions, or ACCESS, model to primary care for more chronic conditions. Many parts of the Medicare Annual Wellness Visit could potentially be delivered through AI tools, the roadmap said.
4. The FDA may adopt a competency-based premarket review for certain AI-enabled devices, similar to how physicians are credentialed. Some regulatory actions could trigger express preemption of state requirements, part of a push for national standards.
5. CMS’ Health Tech Ecosystem has grown from more than 60 company commitments to more than 800. Patient digital data access rose from about 5% to 60% in one year, the agency said.
6. The roadmap cites Microsoft research in which its MAI-DxO tool correctly diagnosed 85.5% of challenging cases, versus about 20% for practicing physicians.
7. CMS flagged risks including hallucinations, uneven performance across populations, commercial conflicts of interest, and privacy and cybersecurity vulnerabilities. The roadmap does not mandate AI adoption or create a new agency.
The roadmap builds on the ACCESS model, announced in December 2025, and the FDA’s TEMPO pilot, which launched in conjunction with ACCESS in January 2026.